The DNA repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT) antagonizes
the genotoxic effects of alkylating agents. MGMT promoter methylation is the key mechanism …

Modern neuropathology serves a key function in the multidisciplinary management of brain
tumor patients. Owing to the recent advancements in molecular neurooncology, the …

Significant gaps exist in our understanding of the causes and clinical management of
glioma. One of the biggest gaps is how best to manage low-grade (World Health …

In recent years, advances in the understanding of low-grade glioma (LGG) biology have
driven new paradigms in molecular markers, diagnostic imaging, operative techniques and …

Purpose: A retrospective analysis of the toxicity and efficacy of temozolomide in advanced
neuroendocrine tumors. Experimental Design: Thirty-six patients with advanced stages of …

Purpose: Recent studies suggest that temozolomide has activity in neuroendocrine tumors.
Low levels of the DNA repair enzyme, O 6-methylguanine DNA methyltransferase (MGMT) …

Over the past 10 years, there has been an increasing use of molecular markers in the
assessment and management of adult malignant gliomas. Some molecular signatures are …

Objective: To evaluate the predictive impact of chromosome 1p/19q deletions on the
response and outcome of progressive low-grade gliomas (LGG) treated with up-front …

O-6-methylguanine-DNA methyltransferase (MGMT) is an abundantly expressed nuclear
protein dealkylating O6-methylguanine (O6-MG) DNA residue, thus correcting the …

The importance of DNA repair as a resistance mechanism in gliomas, the most aggressive
form of brain tumor, is a clinically relevant topic. Recent studies show that not all cells are …